Adjuvant Therapy With Thalidomide After Curative Resection of Hepatocellular Carcinoma

Summary

Postoperative recurrence of hepatocellular carcinoma (HCC) is a major problem after surgical resection. To date, adjuvant chemotherapy or other adjuvant modalities have not been proven effective in preventing or delaying recurrence. The aim of this prospective randomized study was to evaluate the effectiveness of Thalidomide as a postoperative adjuvant regimen in inhibiting the recurrence of HCC

Timeline

Start

2013-07

Primary completion

2015-08

Completion

2019-12

Drugs

Indications